

Haloperidol, HRP conjugate

DAG1164

Lot. No. (See product label)

PRODUCT INFORMATION

Product overview	Haloperidol, HRP conjugate
Antigen Description	Haloperidol is a typical antipsychotic which is used in the treatment of schizophrenia and in the treatment of acute psychotic states and delirium. It has many adverse side effects and the dosage and metabolism of this drug must be closely monitored.
Source	Sedatives
Conjugate	HRP
Form	concentrate
Characteristic	Each conjugate comprises antigen covalently bound to horseradish peroxide and is suitable as a tracer in immunoassay development
Applications	ELISA, Immunoassays, Development of Rapid tests and other immunoassay, antibody recognition assays

PACKAGING

Storage	Can be stored at 2-8°C for up to 3 months and at -20°C for longer term storage.
----------------	---

BACKGROUND

Introduction	Haloperidol is a dopamine antagonist of the typical antipsychotic class of medications. It is a butyrophenone derivative and has pharmacological effects similar to the phenothiazines. Haloperidol is an older antipsychotic used in the treatment of schizophrenia and acute psychotic states and delirium. A long-acting decanoate ester is used as an injection given every four weeks to people with schizophrenia or related illnesses who have poor adherence to medication regimens and suffer frequent relapses of illness, or to overcome the drawbacks inherent to its orally administered counterpart that burst dosage increases risk or intensity of side effects. In some countries, injections of antipsychotics such as haloperidol can be ordered by a court at the request of a psychiatrist.
Keywords	Haloperidol; 4-[4-(4-chlorophenyl)-4-hydroxy-1-piperidyl]-1-(4-fluorophenyl)-butan-1-one; Aloperidin; Bioperidolo; Dozic; Einalon S; fortunat; Galoperidol; Keselan; Mixidol; Pekuces

REFERENCES

1. Healy, David (1996). The psychopharmacologists. 1. London: Chapman and Hall. ISBN 978-1-86036-008-4.
2. Granger B, Albu S (2005). "The haloperidol story". Annals of Clinical Psychiatry : Official Journal of the American Academy of Clinical Psychiatrists 17 (3): 137-40. DOI:10.1080/10401230591002048. PMID 16433054.